desmoplastic small round cell tumor/dijareja

Veza se sprema u međuspremnik

ČlanciKliničkim ispitivanjimaPatenti

Odaberite vrstu sortiranja

5 rezultati

Desmoplastic small-round-cell tumor of the abdomen: A report of two rare cases.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Desmoplastic small-round-cell tumor (DSRCT) is an uncommon type of malignancy, which primarily occurs in adolescent males and develops in the abdominal cavity. The present study reports the case of two manifestations of DSRCT complicated with other diseases, which involved the invasion of the pelvis

The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Background: Desmoplastic small round cell tumor (DSRCT) is a rare aggressive sarcoma that affects children and young adults, and portends poor outcomes despite intensive multimodal treatment approaches. We report toxicity, response, and

Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Desmoplastic small round cell tumor (DSCRT) is an uncommon pediatric tumor with a poor prognosis. Aggressive multimodality therapy is the current treatment approach; however. treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation

Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Irinotecan (CPT-11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. METHODS Over a 2-year period between 2002 and 2004, 32 heavily

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE To determine the maximum tolerated dose and the toxicity profile of the PDGF receptor pathway inhibitor SU101 in pediatric patients with refractory solid tumors, and to define the plasma pharmacokinetics of SU101 and its active metabolite SU0020 in children. METHODS Patients between 3 and

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima